On June 16, 2022, Qin Jihong, party member of Administration for Market Regulation of Hunan Province and Hunan Medical Products Administration, and his party guided IntelliMicro on product registration and declaration on site.
Secretary Qin Jihong was briefed on our Company’s enterprise introduction, technical evolution, product R&D, development strategy and other aspects, understood in detail the progress of our project construction and the problems to be solved, and visited our GMP workshop on the spot.
Secretary Qin Jihong said that IntelliMicro has settled in Changsha as a result of the joint efforts of party committees, governments and departments at all levels. The process of entrepreneurship is very difficult, and the future is bright. He stressed that Hunan Medical Products Administration promotes the development of the medical industry. In particular, its direction, policy and attitude of high-tech innovative technology enterprises represented by IntelliMicro remain unchanged. It implements high-end medical device products registration in a creative way by making the most of relevant policies of the State Council’s Regulations for the Supervision and Administration of Medical Devices, and doing a good job in the registration of IntelliMicro IMIE project’s products which are detailed measures to demonstrate the government’s integrity, to stabilize the basic economy, and to promote the industrial development.
Secretary Qin Jihong required all functional departments of Hunan Medical Products Administration to do a good job in service guarantee, communication and coordination as always, and timely and efficiently solve the problems encountered in the process of product registration and declaration. At the same time, IntelliMicro is required to continue to maintain a sense of urgency and mission, take patient needs as the center, and accelerate the promotion of product registration.
The heads of relevant functional departments of Hunan Medical Products Administration participated in the investigation, discussed on how to accelerate the registration of our company’s project, and expressed that they would fully support and encourage enterprise’s R&D of medical devices for the treatment of rare diseases and the development of enterprises.